Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral influenza vaccine (US Biologic)
- Development stage
- Preclinical
- Lead developer
- US Biologic
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
US Biologic is developing an oral influenza vaccine using its proprietary OrisBio platform technology. The vaccine utilizes recombinant *Bacillus subtilis* spores that express influenza virus antigens. This platform is designed to protect the antigens from the harsh, acidic environment of the stomach, allowing for targeted delivery and release in the duodenum. Once released, the antigens induce both mucosal and systemic immune responses. Developed in partnership with the Biomedical Advanced Research and Development Authority (BARDA) under the "Beyond the Needle" program, the vaccine is intended to be thermostable, eliminating the need for refrigeration and needle-based administration, which could facilitate at-home delivery and improved pandemic preparedness.
- Other names
- OrisBio Oral Flu VaccineUS Biologic Oral Influenza Vaccine
Beyond the preview
Go deeper on oral influenza vaccine (US Biologic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral influenza vaccine (US Biologic).